Bank of New York Mellon Corp Purchases 18,586 Shares of Xencor, Inc. (NASDAQ:XNCR)

Bank of New York Mellon Corp increased its position in Xencor, Inc. (NASDAQ:XNCR) by 4.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 437,152 shares of the biopharmaceutical company’s stock after acquiring an additional 18,586 shares during the quarter. Bank of New York Mellon Corp owned about 0.62% of Xencor worth $10,046,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of XNCR. GAMMA Investing LLC increased its stake in shares of Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 508 shares during the period. KBC Group NV increased its position in Xencor by 63.5% in the 3rd quarter. KBC Group NV now owns 3,123 shares of the biopharmaceutical company’s stock worth $63,000 after buying an additional 1,213 shares during the period. Quarry LP lifted its holdings in shares of Xencor by 111.4% during the third quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company’s stock worth $80,000 after buying an additional 2,108 shares during the last quarter. Rockefeller Capital Management L.P. bought a new stake in shares of Xencor in the third quarter valued at approximately $205,000. Finally, Point72 Asia Singapore Pte. Ltd. grew its stake in shares of Xencor by 8.5% in the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 12,156 shares of the biopharmaceutical company’s stock worth $244,000 after acquiring an additional 949 shares during the last quarter.

Xencor Stock Performance

NASDAQ XNCR opened at $12.87 on Friday. Xencor, Inc. has a twelve month low of $12.80 and a twelve month high of $27.24. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.01. The stock has a market cap of $906.85 million, a P/E ratio of -4.02 and a beta of 0.74. The company’s 50-day simple moving average is $17.59 and its 200 day simple moving average is $20.45.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The company had revenue of $52.79 million for the quarter, compared to analyst estimates of $17.14 million. As a group, research analysts forecast that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

XNCR has been the subject of several research analyst reports. StockNews.com cut shares of Xencor from a “hold” rating to a “sell” rating in a research note on Friday. Piper Sandler raised shares of Xencor from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $20.00 to $30.00 in a research report on Monday, December 2nd. Finally, Wells Fargo & Company decreased their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating on the stock in a research report on Friday, February 28th. One investment analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.38.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.